Journal
CLINICAL SCIENCE
Volume 131, Issue 19, Pages 2469-2488Publisher
PORTLAND PRESS LTD
DOI: 10.1042/CS20170033
Keywords
-
Categories
Funding
- Alzheimer Nederland [14502, 12506]
- CAVIA [733050202]
- NIH [NS092696]
- CAVIA
Ask authors/readers for more resources
Cerebral amyloid angiopathy (CAA), due to vascular amyloid beta (A beta) deposition, is a risk factor for intracerebral haemorrhage and dementia. CAA can occur in sporadic or rare hereditary forms, and is almost invariably associated with Alzheimer's disease (AD). Experimental (animal) models are of great interest in studying mechanisms and potential treatments for CAA. Naturally occurring animal models of CAA exist, including cats, dogs and non-human primates, which can be used for longitudinal studies. However, due to ethical considerations and low throughput of these models, other animal models are more favourable for research. In the past two decades, a variety of transgenic mouse models expressing the human A beta precursor protein (APP) has been developed. Many of these mouse models develop CAA in addition to senile plaques, whereas some of these models were generated specifically to study CAA. In addition, other animal models make use of a second stimulus, such as hypoperfusion or hyperhomocysteinemia (HHcy), to accelerate CAA. In this manuscript, we provide a comprehensive review of existing animal models for CAA, which can aid in understanding the pathophysiology of CAA and explore the response to potential therapies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available